Apremilast for Discoid Lupus Erythematosus: Results of a Phase 2, Open-Label, Single-Arm, Pilot Study

被引：1
|
作者：
De Souza, Aieska
Strober, Bruce E.
Merola, Joseph F.
Oliver, Stephen
Franks, Andrew G., Jr. [1 ,2 ]
机构：
[1] NYU, Langone Med Ctr, ACC, Ronald O Perelman Dept Dermatol,Sch Med, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Med Rheumatol, New York, NY 10016 USA
来源：
JOURNAL OF DRUGS IN DERMATOLOGY | 2012年 / 11卷 / 10期
关键词：
INHIBITOR; PSORIASIS;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Background: Discoid lupus erythematosus (DLE) is a chronic inflammatory disorder mediated by Th1 cells. Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of 11,12, 11,23, TNF-a, INF-y with subsequent suppression of Th1 and Th17-mediated immune responses, and proven clinical efficacy for psoriasis as well as rheumatoid and psoriatic arthritis. Observations: Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) showed a significant (P<0.05) decrease after 85 days of treatment with apremilast 20 mg twice daily in 8 patients with active discoid lupus. The adverse events related to the drug were mild and transient. Conclusions: This is the first open label study to use apremilast as a treatment modality for discoid lupus. Our observations indicate that apremilast may constitute a safe and effective therapeutic option for DLE.
引用
收藏
页码：1224 / 1226
页数：3
相关论文
共 50 条
  • [1] Ruxolitinib cream for discoid lupus erythematosus: An open-label pilot study of ten patients
    Bender, A. M.
    Kaur, J.
    Babkowski, N.
    Richardson, C. T.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S163 - S163
  • [2] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [3] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    [J]. Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [4] A single-arm, phase II open-label trial to investigate the efficacy and safety of intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE)
    Yusof, M. Y. M.
    Wittmann, M.
    Fernandez, C.
    Wilson, D.
    Edward, S.
    Abignano, G.
    Alase, A.
    Sharples, L.
    Laws, P.
    Goodfield, M.
    Vital, E. M.
    Emery, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (06) : E191 - E192
  • [5] An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
    Agulnik, Mark
    Schulte, Brian
    Robinson, Steven
    Hirbe, Angela C.
    Kozak, Kevin
    Chawla, Sant P.
    Attia, Steven
    Rademaker, Alfred
    Zhang, Hui
    Abbinanti, Susan
    Cehic, Rasima
    Monga, Varun
    Milhem, Mohammed
    Okuno, Scott
    Van Tine, Brian A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 154 : 201 - 208
  • [6] Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
    Schwartzberg, Lee
    Hermann, Robert
    Flinn, Ian
    Flora, Douglas
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Myrand, Scott P.
    Nguyen, Tuan S.
    Dreyling, Martin
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 91 - 97
  • [7] Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
    Lai, Zhi-Wei
    Kelly, Ryan
    Winans, Thomas
    Marchena, Ivan
    Shadakshari, Ashwini
    Yu, Julie
    Dawood, Maha
    Garcia, Ricardo
    Tily, Hajra
    Francis, Lisa
    Faraone, Stephen V.
    Phillips, Paul E.
    Perl, Andras
    [J]. LANCET, 2018, 391 (10126): : 1186 - 1196
  • [8] Opicapone OASIS study in Parkinson's: design of an open-label, single-arm, pilot trial
    Costa, R.
    Trenkwalder, C.
    Ferreira, J.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 628 - 628
  • [9] Effect of Facial Cosmetic Acupuncture on Facial Elasticity: An Open-Label, Single-Arm Pilot Study
    Yun, Younghee
    Kim, Sehyun
    Kim, Minhee
    Kim, KyuSeok
    Park, Jeong-Su
    Choi, Inhwa
    [J]. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [10] An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
    Gottlieb, A. B.
    Strober, B.
    Krueger, J. G.
    Rohane, P.
    Zeldis, J. B.
    Hu, C. C.
    Kipnis, C.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1529 - 1538
12345